Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cost of Revenue: 2009-2024

Historic Cost of Revenue for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $309.7 million.

  • UNITED THERAPEUTICS's Cost of Revenue rose 21.42% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.9 million, marking a year-over-year increase of 17.09%. This contributed to the annual value of $309.7 million for FY2024, which is 20.27% up from last year.
  • UNITED THERAPEUTICS's Cost of Revenue amounted to $309.7 million in FY2024, which was up 20.27% from $257.5 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Cost of Revenue ranged from a high of $309.7 million in FY2024 and a low of $108.1 million during FY2020.
  • In the last 3 years, UNITED THERAPEUTICS's Cost of Revenue had a median value of $257.5 million in 2023 and averaged $239.6 million.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Cost of Revenue fell by 8.08% in 2020, and later spiked by 69.85% in 2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Cost of Revenue (Yearly) stood at $108.1 million in 2020, then grew by 13.32% to $122.5 million in 2021, then increased by 23.76% to $151.6 million in 2022, then spiked by 69.85% to $257.5 million in 2023, then rose by 20.27% to $309.7 million in 2024.